Role of complement and perspectives for intervention in ischemia-reperfusion damage.
Reperfusion of an organ following prolonged ischemia instigates the pro-inflammatory and pro-coagulant response of ischemia / reperfusion (IR) injury. IR injury is a wide-spread pathology, observed in many clinically relevant situations, including myocardial infarction, stroke, organ transplantation, sepsis and shock, and cardiovascular surgery on cardiopulmonary bypass. Activation of the classical, alternative, and lectin complement pathways and the generation of the anaphylatoxins C3a and C5a lead to recruitment of polymorphonuclear leukocytes, generation of radical oxygen species, up-regulation of adhesion molecules on the endothelium and platelets, and induction of cytokine release. Generalized or pathway-specific complement inhibition using protein-based drugs or low-molecular-weight inhibitors has been shown to significantly reduce tissue injury and improve outcome in numerous in-vitro, ex-vivo, and in-vivo models. Despite the obvious benefits in experimental research, only few complement inhibitors, including C1-esterase inhibitor, anti-C5 antibody, and soluble complement receptor 1, have made it into clinical trials of IR injury. The results are mixed, and the next objectives should be to combine knowledge and experience obtained in the past from animal models and channel future work to translate this into clinical trials in surgical and interventional reperfusion therapy as well as organ transplantation.
Institute of Pathology, University of Bern, Switzerland.
Yara
Y
Banz
Robert
R
Rieben
D000706:Anaphylatoxins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D003167:Complement Activation / Q000187:drug effects* / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007511:Ischemia / Q000150:complications* / Q000188:drug therapy; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control
D000706:Anaphylatoxins; D007155:Immunologic Factors; D003165:Complement System Proteins